#USA #San Diego #Field Medical #Ablation System #Heart Rhythm

Field Medical Unveils Innovative PFA Technology at Heart Rhythm 2025

Field Medical Inc., the vanguard of cardiac pulsed field ablation (PFA) technology, is making a significant impact at the 46th annual Heart Rhythm Society (HRS) meeting, being held from April 24-27, 2025, in sunny San Diego, California. This year’s event, renowned for gathering over 9,000 healthcare professionals and leading experts in electrophysiology, features an array of cutting-edge presentations, including details about the FieldForce™ Ablation System set to address complex cardiac conditions.

A Leap Forward in Cardiac Treatment

Among the highlights is the unprecedented presentation of results from the first-in-human evaluation of focal PFA targeting scar-related ventricular tachycardia (VT). This condition, characterized by the presence of dense fibrotic substrates, is notoriously resistant to traditional management techniques. The unveiling of these findings represents a pivotal advancement in the treatment landscape, showcasing a novel approach that could redefine care for patients plagued by scar-related VT.

Field Medical’s FieldForce™ Ablation System is engineered to achieve focal PFA capable of creating full-thickness, transmural lesions, thereby targeting the heart’s critical areas with precision. The device's ability to penetrate from the endocardium to the epicardium indicates a revolutionary method for addressing complex cardiac arrhythmias that have long posed challenges to even the most seasoned electrophysiologists.

Showcasing Science and Innovation

Field Medical's presence at the Heart Rhythm meeting is robust, featuring eight scientific presentations that span live case demonstrations, poster sessions, and a flagship symposium. The cornerstone of this will be the late-breaking VCAS trial set for April 27, which will reveal acute results from their pioneering investigation on the application of focal PFA for scar-related VT.

Dr. Steven Mickelsen, CEO and founder of Field Medical, emphasized the ongoing struggle that ventricular tachycardia represents for electrophysiologists globally. He remarked, “For decades, VT has presented challenges due to the complexity of its scar substrate. With FieldForce, we aren’t merely iterating; we are redefining what is achievable in the electrophysiology domain.” This sentiment underscores the potential of the FieldForce system to navigate territories of unmet clinical need and expand the options available for treating complex conditions.

Diverse Learning Opportunities

Within the Heart Rhythm framework, several presentations will enrich the discourse on PFA technology. Among the scheduled highlights includes:

• - New Arrhythmia Technologies Retreat with Dr. Steven Mickelsen, exploring innovative methodologies in the space.
• - Live Case Demonstrations: Featuring the capabilities of PFA technology in real-time, exhibiting the advanced applications of FieldForce.
• - Poster Presentations: Covering diverse topics, including investigations into the treatment of refractory VT with investigational PFA systems and insights into MRI scar modulation post-PFA treatment.

Field Medical has meticulously crafted a schedule that emphasizes education and practical training for attendees, as well as the role of PFA innovations in addressing current challenges in electrophysiology.

Commitment to Advancement

Established in 2022, Field Medical is propelled by its mission to advance next-generation pulsed field ablation technologies. Under the leadership of Dr. Steven Mickelsen, the company is committed to refining these technologies to meet the evolving demands in cardiac care. Their work has garnered significant recognition, including the FDA’s Breakthrough Device Designation and inclusion in the TAP Pilot Program.

With the FieldForce™ Ablation System poised to revolutionize approaches to VT ablation, Field Medical is at the forefront, inspiring hope for enhanced patient outcomes and setting new standards in the field of electrophysiology. Attendees and interested parties are encouraged to follow Field Medical's progress and visit their site for further information. Together, they stand on the precipice of transformational change in cardiac treatment methodologies.